SUPN Supernus Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: SUPN
- PE Ratio
The current P/E ratio for Supernus Pharmaceuticals stock as of Jun 4, 2025 is 28.58. This is calculated based on the TTM EPS of $1.13 and the stock price of $32.3 per share. The PE ratio has decreased by 70% from its last 4 quarters average of 95.5.
SUPN PE ratio history
The average historical PE ratio of Supernus Pharmaceuticals for the last ten years is 73.41. The current price-to-earnings ratio of 28.58 is 61% less than the historical average. Analyzing the last ten years, SUPN's PE ratio reached its highest point in the Dec 2023 quarter at 1,447, when the price was $28.94 and the EPS was $0.02. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.
Supernus Pharmaceuticals PE ratio by year
Maximum annual increase: 4,483.47% in 2023
Maximum annual decrease: -98.13% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 26.99 | -98.13% | $36.16 | $1.34 |
| 2023 | 1,447 | 4,483.47% | $28.94 | $0.02 |
| 2022 | 31.57 | 9.35% | $35.67 | $1.13 |
| 2021 | 28.87 | 176.53% | $29.16 | $1.01 |
| 2020 | 10.44 | -4.92% | $25.16 | $2.41 |
| 2019 | 10.98 | -29.62% | $23.72 | $2.16 |
| 2018 | 15.6 | -55.77% | $33.22 | $2.13 |
| 2017 | 35.27 | 157.07% | $39.85 | $1.13 |
| 2016 | 13.72 | -70.39% | $25.25 | $1.84 |
| 2015 | 46.34 | N/A | $13.44 | $0.29 |
| 2014 | N/A | N/A | $8.3 | -$0.26 |
| 2013 | N/A | N/A | $7.54 | -$2.9 |
| 2012 | N/A | N/A | $7.17 | -$2.72 |
| 2011 | N/A | N/A | N/A | $31.39 |
| 2010 | N/A | N/A | N/A | -$26.38 |
Supernus Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 28.98 | 7.37% | $32.75 | $1.13 |
| Dec 2024 | 26.99 | -6.51% | $36.16 | $1.34 |
| Sep 2024 | 28.87 | -90.29% | $31.18 | $1.08 |
| Jun 2024 | 297.22 | N/A | $26.75 | $0.09 |
| Mar 2024 | N/A | N/A | $34.11 | -$0.29 |
| Dec 2023 | 1,447 | 2,366.76% | $28.94 | $0.02 |
| Sep 2023 | 58.66 | 54.17% | $27.57 | $0.47 |
| Jun 2023 | 38.05 | 0.82% | $30.06 | $0.79 |
| Mar 2023 | 37.74 | 19.54% | $36.23 | $0.96 |
| Dec 2022 | 31.57 | -33.79% | $35.67 | $1.13 |
| Sep 2022 | 47.68 | 79.72% | $33.85 | $0.71 |
| Jun 2022 | 26.53 | 14.11% | $28.92 | $1.09 |
| Mar 2022 | 23.25 | -19.47% | $32.32 | $1.39 |
| Dec 2021 | 28.87 | 67.75% | $29.16 | $1.01 |
| Sep 2021 | 17.21 | 6.17% | $26.67 | $1.55 |
SUPN Price vs fair value
SUPN average PE ratio chart
The current PE ratio of SUPN is under its 3, 5 and 10-year averages.
SUPN PE vs peers
SUPN's PE ratio is less than its peer stock LLY, but it is above JNJ's and ABT's. Supernus Pharmaceuticals is currently trading at a higher PE ratio (28.58) than its peers average of 25.21.
| Stock name | PE ratio | Market cap |
|---|---|---|
| UTHR UNITED THERAPEUTICS Corp | 11.96 | $14.61B |
| JNJ Johnson & Johnson | 16.91 | $368.66B |
| ABT Abbott Laboratories | 17.22 | $231.33B |
| BMY Bristol Myers Squibb Co | 17.89 | $97.58B |
| SUPN Supernus Pharmaceuticals Inc | 28.58 | $1.81B |
| LLY ELI LILLY & Co | 62.06 | $725.81B |
Frequently asked questions
What is Supernus Pharmaceuticals's PE ratio?
The price to earnings ratio for SUPN stock as of Jun 4, 2025, stands at 28.58.
What is the 3-year average PE ratio for Supernus Pharmaceuticals (SUPN)?
Over the last 3 years, the average PE ratio for SUPN stock is 188.12.
What is the 5-year average PE ratio for Supernus Pharmaceuticals (SUPN)?
Over the last 5 years, the average PE ratio for SUPN stock is 115.62.
What is the highest PE ratio for SUPN?
The highest quarterly PE ratio in the last ten years has been 1,447 and it was in the Dec 2023 quarter.
How does the current PE ratio for SUPN compare to its historical average?
The current PE ratio of SUPN is 61% lower than the 10-year historical average.
How is SUPN's PE ratio calculated (Supernus Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Jun 4, 2025), Supernus Pharmaceuticals's share price is $32.3. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.13. Therefore, Supernus Pharmaceuticals's price to earnings ratio for today is 28.58. PE RATIO(28.58) = STOCK PRICE($32.3) / TTM EPS($1.13)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.